C4 Therapeutics, Inc. (CCCC) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	35.0M	35.9M	35.6M	20.8M	31.1M
Cost of Revenue	1.8M	8.0M	—	7.7M	—
Gross Profit	33.2M	28.0M	35.6M	13.0M	31.1M
Operating Expenses
R&D Expense	100.0M	104.2M	110.6M	117.7M	117.8M
SG&A Expense	34.2M	36.2M	42.1M	42.1M	42.8M
General & Admin Expense	36.0M	36.2M	42.1M	42.1M	42.8M
Selling & Marketing Expense	(1.8M)	—	—	—	—
Other Expenses	10.7M	(8.0M)	2.4M	(7.7M)	—
Total Operating Expenses	145.0M	132.5M	155.2M	152.1M	160.6M
Cost and Expenses	146.8M	140.4M	155.2M	159.8M	160.6M
Operating Income (EBIT)	(111.8M)	(104.5M)	(119.6M)	(139.0M)	(129.5M)
Non-Operating
Interest Income	10.5M	10.3M	14.4M	9.8M	3.6M
Interest Expense	—	—	—	1.4M	2.2M
Net Interest Income	10.5M	10.3M	14.4M	8.4M	1.4M
Other Non-Op Income/Expense	10.5M	(384.0K)	14.4M	7.8M	1.4M
Non-Operating Income (excl Interest)	(10.5M)	384.0K	(14.4M)	(9.2M)	(3.6M)
EBT (Pre-Tax Income)	(101.3M)	(104.9M)	(105.2M)	(131.2M)	(128.2M)
Income Tax Expense	121.0K	121.0K	131.0K	1.3M	—
Bottom Line
Net Income	(101.4M)	(105.0M)	(105.3M)	(132.5M)	(128.2M)
Earnings from Cont. Ops	(101.4M)	(105.0M)	(105.3M)	(132.5M)	(128.2M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(101.4M)	(105.0M)	(105.3M)	(132.5M)	(128.2M)
Per Share
Basic EPS	($1.00)	($1.27)	($1.52)	($2.67)	($2.62)
Diluted EPS	($1.00)	($1.27)	($1.52)	($2.67)	($2.62)
Revenue Per Share	$0.27	$0.43	$0.51	$0.42	$0.64
Shares
Basic Shares Outstanding	130.7M	82.9M	69.4M	49.6M	48.9M
Diluted Shares Outstanding	130.7M	82.9M	69.4M	49.6M	48.9M
Profitability Metrics
EBITDA	(98.3M)	(102.9M)	(103.4M)	(122.1M)	(124.3M)
D&A	3.0M	2.0M	1.8M	7.7M	1.7M
EBIT	(101.3M)	(104.9M)	(105.2M)	(129.8M)	(126.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026